Kura Oncology (NASDAQ:KURA) Receives Overweight Rating from Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of Kura Oncology (NASDAQ:KURA) in a research report released on Wednesday, Benzinga reports.

Several other research analysts have also recently weighed in on KURA. HC Wainwright reiterated a “buy” rating and set a $32.00 price target on shares of Kura Oncology in a research report on Wednesday. Wedbush reiterated an “outperform” rating and set a $37.00 price target on shares of Kura Oncology in a research report on Monday. UBS Group initiated coverage on Kura Oncology in a research report on Thursday, October 24th. They set a “buy” rating and a $27.00 price target for the company. StockNews.com cut Kura Oncology from a “hold” rating to a “sell” rating in a research report on Thursday, August 22nd. Finally, JMP Securities reiterated a “market outperform” rating and set a $32.00 price target on shares of Kura Oncology in a research report on Monday, August 12th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $28.83.

Kura Oncology Stock Up 1.3 %

NASDAQ KURA traded up $0.23 during trading on Wednesday, hitting $18.07. The company’s stock had a trading volume of 70,185 shares, compared to its average volume of 890,846. The company has a debt-to-equity ratio of 0.02, a current ratio of 14.94 and a quick ratio of 14.94. The company has a market cap of $1.38 billion, a PE ratio of -8.00 and a beta of 0.86. The business’s 50 day simple moving average is $18.90 and its 200-day simple moving average is $20.01. Kura Oncology has a fifty-two week low of $8.17 and a fifty-two week high of $24.17.

Kura Oncology (NASDAQ:KURA) last released its earnings results on Thursday, August 8th. The company reported ($0.59) EPS for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.04. During the same period last year, the company posted ($0.53) EPS. Kura Oncology’s revenue was up .0% compared to the same quarter last year. On average, equities analysts anticipate that Kura Oncology will post -2.46 EPS for the current fiscal year.

Hedge Funds Weigh In On Kura Oncology

A number of institutional investors and hedge funds have recently added to or reduced their stakes in KURA. Harbor Capital Advisors Inc. lifted its stake in shares of Kura Oncology by 21.9% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 47,295 shares of the company’s stock valued at $924,000 after purchasing an additional 8,505 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in Kura Oncology by 64.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 14,739 shares of the company’s stock worth $288,000 after purchasing an additional 5,788 shares during the period. nVerses Capital LLC purchased a new stake in Kura Oncology during the 3rd quarter worth about $25,000. Quarry LP purchased a new position in shares of Kura Oncology in the 2nd quarter valued at about $196,000. Finally, Alethea Capital Management LLC increased its holdings in shares of Kura Oncology by 2.4% in the 2nd quarter. Alethea Capital Management LLC now owns 265,906 shares of the company’s stock valued at $5,475,000 after acquiring an additional 6,300 shares during the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.